on Heidelberg Pharma AG (isin : DE000A11QVV0)
Heidelberg Pharma to Present New Clinical Data on HDP-101 at IMS 2024
Heidelberg Pharma AG has announced new clinical data for its lead ATAC candidate, HDP-101. These findings will be presented at the 21st International Myeloma Society Annual Meeting in Rio De Janeiro from 25 to 28 September 2024. HDP-101 is an Antibody-Amanitin Drug Conjugate targeting relapsed or refractory multiple myeloma, aiming to fill an unmet medical need.
Professor Marc-Steffen Raab from the University Hospital Heidelberg will present clinical findings from five patient cohorts involved in the Phase I/IIa study. Previous data showed biological activity in three out of five patients, with partial remission observed. The trial is now in its sixth cohort, with further data anticipated at future scientific gatherings.
Additionally, Heidelberg Pharma will host an R&D Webinar on 15 October 2024 to discuss these developments in more detail.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news